Silodosin: A Review of Its Use in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia
- 521 Downloads
Silodosin is a highly selective α1A-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Oral silodosin had a rapid onset of effect in men with lower urinary tract symptoms (LUTS) associated with BPH, with improvements seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life in well-designed, 12-week trials. Silodosin was noninferior to tamsulosin in terms of improving LUTS associated with BPH. The efficacy of silodosin was maintained in 9-month extension studies and was also seen in a phase IV study conducted in a real-world setting. Silodosin was generally well tolerated and was associated with a low risk of orthostatic hypotension. Abnormal ejaculation was the most commonly reported adverse event, although few patients discontinued treatment with silodosin because of this adverse event. In conclusion, silodosin is a useful option for the treatment of LUTS associated with BPH.
KeywordsBenign Prostatic Hyperplasia Lower Urinary Tract Symptom Orthostatic Hypotension International Prostate Symptom Score Tamsulosin
The preparation of this review was not supported by any external funding. Gillian Keating is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
- 11.European Medicines Agency. Silodyx (silodosin): EU summary of product characteristics. 2014. http://www.ema.europa.eu/. Accessed 8 Dec 2014.
- 15.European Medicines Agency. Silodyx (silodosin): EU public assessment report. 2010. http://www.ema.europa.eu/. Accessed 8 Dec 2014.
- 17.Watson Pharma Inc. Rapaflo® (silodosin) capsules: US prescribing information. 2013. http://www.actavis.com/. Accessed 8 Dec 2014.
- 20.Kissei Pharmaceutical Co Ltd. Urief® (silodosin) capsules: Japanese prescribing information. 2008. http://www.e-search.ne.jp/~jpr/HTML/EJPR002.HTM. Accessed 8 Dec 2014.
- 22.Chapple CR, Montorsi F, Tammela TLJ, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–52.PubMedCrossRefGoogle Scholar
- 25.Choo M-S, Song M, Kim JH, et al. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study. Urology. 2014;83(4):875–81.PubMedCrossRefGoogle Scholar
- 28.Chapple CR. The ‘Silodosin in Real-life Evaluation (SiRE)’ study: a European phase IV clinical study with silodosin in the treatment of LUTS/BPH [poster]. In: 29th Annual Congress of the European Association of Urology; 2014.Google Scholar
- 31.Eisenhardt A, Schneider T, Cruz F, et al. Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol. 2014;32(5):1119–25.PubMedCrossRefGoogle Scholar
- 33.Novara G, Chapple CR, Montorsi F. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms associated with benign prostatic enlargement: subgroup analyses of efficacy and safety data. BJU Int. 2014. doi: 10.1111/bju.12906.
- 35.Tammela T, Chapple CR. Effects of the long-term treatment with silodosin in men with LUTS suggestive of BPH: a 9-month, open-label extension study [abstract no. 755]. In: 27th Congress of the European Association of Urology; 2012.Google Scholar
- 38.Ipekci T, Akin Y, Hoscan B, et al. Intraoperative floppy iris syndrome associated with silodosin. Acta Ophthalmol (Copenh). 2014. doi: 10.1111/aos.12549.
- 43.Boehringer Ingelheim Pharmaceuticals Inc. Flomax (tamsulosin hydrochloride) capusles 0.4 mg: US prescribing information. 2014. http://www.4flomax.com. Accessed 8 Dec 2014.
- 44.Boehringer Ingelheim. Flomax Relief MR (tamsulosin): UK summary of product characteristics. 2014. http://www.medicines.org.uk/emc/medicine/22738. Accessed 8 Dec 2014.
- 47.Novara G, Tubaro A, Sanseverino R, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol. 2013;31(4):997–1008.PubMedCrossRefGoogle Scholar
- 55.Tsumura H, Satoh T, Ishiyama H, et al. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int J Radiat Oncol Biol Phys. 2011;81(4):e385–92.PubMedCrossRefGoogle Scholar
- 56.Oyama N, Aoki Y, Ito H, et al. Alpha 1-adrenoceptor blocker may improve not only voiding but also storage lower urinary tract symptoms caused by 125I brachytherapy for prostate cancer. ISRN Urol. 2014. doi: 10.1155/2014/140654.
- 58.Sur RL, Shore N, L’Esperance J, et al. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. Eur Urol. 2014. doi: 10.1016/j.eururo.2014.10.049.